Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C

Niemann-Pick Disease, Type C Clinical Trial

Official title:

Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05588167
• Other study ID #: 10001018
• Secondary ID: 001018-CH
• Status: Recruiting
• Start date: November 28, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: January 23, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Derek Alexander
• Phone: (301) 827-0387
• Email: derek.alexander[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talking, or dementia. But symptoms can vary among different people with the disease. Some may have seizures, while others do not, for example. Some people begin showing symptoms in childhood; in others, symptoms may not appear until they are adults. Researchers want to learn more about why NPC affects people differently. This natural history study will gather data from people with NPC in order to understand more about the disease and how it affects the body.

Objective:

This study will create the first and largest database about NPC.

Eligibility:

People of any age who have NPC.

Design:

Participants will have blood drawn from a vein. This will happen only once. The blood will be used to analyze the participants DNA.

The participants medical records will be reviewed. The study team will collect data on participants NPC diagnosis and symptoms; they will record how long participants have had each symptom. The study team will also collect data on each participants age, sex, race, height, weight, medications, and other test results.

The study team will communicate with participants. They will discuss the study and answer any questions.

Participants will receive up to $190.

Description:

Study Description:

The primary objective of this protocol is to investigate the phenotypic heterogeneity of NPC by using clinical and genomic data, and to establish a comprehensive database to facilitate future investigations.

Objectives:

1. Identify correlations between NPC clinical phenotypic findings and genomic markers to facilitate the understanding of the heterogeneity of this disease.

2. Identify genetic contributions to NPC disease progression that can be utilized as potential therapeutic targets.

3. Establish the first and largest database of genomic and phenotypic information for NPC to benefit the NPC research and patient community.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months and older

Eligibility

• INCLUSION CRITERIA;

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, any age, demographic or ethnic background will be eligible for this study

4. Diagnosis of NPC will be based on clinical, biochemical or molecular testing.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Unwilling to provide consent

2. Unable to provide biospecimen to obtain DNA

3. Unable to provide medical records or clinical data

Related Conditions & MeSH terms

• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Niemann-Pick Disease, Type C
• Niemann-Pick Diseases
• Pick Disease of the Brain

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical data, genomic markers	Identify correlations between NPC clinical phenotypic findings and genomic markers to facilitate the understanding of the heterogeneity of this disease.	2 years
Primary	Whole genome	Identify genetic contributions to NPC disease progression that can be utilized as potential therapeutic targets.	2 years

External Links

•   NIH Clinical Center Detailed Web Page